Anna P. Sokolenko

St
Saint Petersburg, SPE, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

An Endemic Region of Thiamine-Responsive Megaloblastic Anemia Caused by an SLC19A2 c.1223+1G>A Founder Mutation.

An Endemic Region of Thiamine-Responsive Megaloblastic Anemia Caused by an SLC19A2 c.1223+1G>A Founder Mutation.

Journal: International journal of molecular sciences

Published: April 30, 2026

Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas.

Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas.

Journal: International journal of molecular sciences

Published: October 26, 2025

5'UTR gene regions in germline DNA sequencing panels: lessons from the analysis of breast and ovarian cancer patients of Tatar and Bashkir ethnic origin.

5'UTR gene regions in germline DNA sequencing panels: lessons from the analysis of breast and ovarian cancer patients of Tatar and Bashkir ethnic origin.

Journal: Familial cancer

Published: March 08, 2025

Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers.

Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers.

Journal: Exploration of targeted anti-tumor therapy

Published: February 08, 2025

Asymptomatic Bloom syndrome diagnosed by chance in a patient with breast cancer.

Asymptomatic Bloom syndrome diagnosed by chance in a patient with breast cancer.

Journal: Familial cancer

Published: June 17, 2024

Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.

Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.

Journal: medRxiv : the preprint server for health sciences

Published: March 18, 2024

Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer.

Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer.

Journal: NPJ genomic medicine

Published: March 14, 2024

Northern origin of the BRCA2 c.5286 T > G founder allele.

Northern origin of the BRCA2 c.5286 T > G founder allele.

Journal: Breast cancer research and treatment

Published: November 08, 2023

Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.

Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.

Journal: Breast cancer research and treatment

Published: July 26, 2023

Correction to: Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-β/SMAD signaling.

Correction to: Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-β/SMAD signaling.

Journal: Breast cancer research and treatment

Published: April 20, 2023

Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation.

Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation.

Journal: Pathobiology : journal of immunopathology, molecular and cellular biology

Published: April 14, 2023

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients.

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients.

Journal: International journal of molecular sciences

Published: December 18, 2022

Showing 1-12 of 71

Last Updated: 09/26/2026